CagriSema Weight Loss Hits New High in Women

CagriSema Weight Loss reached a new milestone this week, as Novo Nordisk reported that women in a late-stage trial shed an average of a quarter of their body weight over roughly sixteen months, according to data presented at a medical meeting in San Diego and reported by Reuters.

The figures come from a fresh analysis of about two thousand three hundred women enrolled in the phase 3 REDEFINE 1 study. Participants on a 2.4-milligram weekly dose lost an average of 25% of their body weight after 68 weeks, compared with 3% for women taking a placebo. Both sets of numbers assume patients stayed on treatment without interruption.

The mechanism behind the shot explains why researchers expected a step up. Semaglutide mimics a gut hormone that curbs appetite and slows digestion, while cagrilintide mimics amylin, a pancreatic hormone involved in satiety signaling. Combining them is meant to attack hunger from two directions at once, rather than pushing a single pathway harder. That dual-action logic is now the industry's favorite template: after years of one-hormone drugs, nearly every major obesity pipeline has a combination candidate aimed at squeezing out a few more percentage points of weight loss without proportionally more side effects.

Why the women's data matters

The new breakdown also split results by stage of the menopause transition, and the drug held up across every group. Premenopausal participants lost nearly twenty-seven percent of their body weight on average, those in the transition lost close to twenty-five percent, and postmenopausal participants lost roughly twenty-three percent. Placebo groups at each stage lost about two percent. The company also reported reductions in abdominal fat, measured by waist circumference, across the overall female population and within each subgroup.

"Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan," said Michelle Skinner Moore, vice president of medical affairs at the Danish drugmaker, in comments carried by Reuters.

A two-hormone bet on the next generation

CagriSema pairs semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, an amylin analog that acts on a separate satiety-related pathway. The idea is that hitting two biological targets at once can deliver more weight loss than GLP-1 drugs manage on their own. The company views the experimental shot as a potential successor to its blockbuster Wegovy franchise, which faces patent expiries after 2030, and both Novo and rival Eli Lilly have been building pipelines around next-generation combinations as they fight for ground in the fast-growing obesity market. Lilly's own contender, retatrutide, takes a different approach as a triple hormone receptor agonist, and early trial results have drawn surgery-level comparisons.

The catch: the analysis came after the fact

There is an important asterisk on the headline numbers. The women's figures are a post hoc analysis, conducted after the trial had already met its primary goals, which the company itself described as hypothesis-generating and in need of further study. In the full trial population of more than three thousand four hundred adults, the drug led to average weight loss of 22.7%, which fell short of the twenty-five percent target the company had originally set. CagriSema Weight Loss data may look like a leap forward, but the shot remains experimental and unapproved, with no announced price, launch date, or coverage picture for patients.

For a generation living through the GLP-1 era, the pattern is familiar: big trial numbers first, hard questions later. Safety scrutiny of the drug class has intensified as use has spread, including new research linking the medications to a rare vision condition, and doctors stress that these analyses do not change how anyone should think about treatment today. The deeper conversation about bodies, medicine, and pressure to shrink is worth having too, because changing your shape does not automatically change how you feel about it. For now, the takeaway is simple: this is a promising data point from an experimental drug, not a prescription pad reality, and the next chapter depends on regulators, pricing, and bigger studies.